Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C481-mutated BTK with equal low nM potency.
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study / Cohen, J.B., Shah, N.N., Alencar, A.J., Gerson, J.N., Patel, M.R., Fakhri, B., Jurczak, W., Tan, X.N., Lewis, K.L., Fenske, T., Coombs, C.C., Flinn, I.W., Lewis, D.J., Gouill, S.L., Palomba, M.L., Woyach, J.A., Pagel, J.M., Lamanna, N., Barve, M.A., Ghia, P., et al.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2669. - 22 Suppl 2:(2022), pp. S394-S395. [10.1016/S2152-2650(22)01569-5]
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
Ghia, Paolo
;
2022-01-01
Abstract
Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C481-mutated BTK with equal low nM potency.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
